1-allyl-6-bromo-1H-benzo[d][1,3]oxazine-2,4-dione | 1131587-69-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 1-allyl-6-bromo-1H-benzo[d][1,3]oxazine-2,4-dione
• 英文别名: 6-bromo-1-prop-2-enyl-3,1-benzoxazine-2,4-dione
• CAS: 1131587-69-3
• 化学式: C₁₁H₈BrNO₃
• 分子量: 282.093
• InChiKey: LUFXAKHXACKXCZ-UHFFFAOYSA-N

物化性质

• 沸点：
  387.1±52.0 °C(Predicted)
• 密度：
  1.596±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  1-allyl-6-bromo-1H-benzo[d][1,3]oxazine-2,4-dione 在 sodium hydroxide 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 甲苯 为溶剂， 反应 8.5h， 生成 2-(6-Bromo-2,4-dioxo-1-prop-2-enylquinazolin-3-yl)acetic acid
  参考文献：
  名称：

  Quinazolineacetic acids and related analogs as aldose reductase inhibitors

  摘要：

  A variety of 2,4-dioxoquinazolineacetic acids (10, 11) were synthesized as hybrids of the known aldose reductase inhibitors alrestatin (8), ICI-105,552 (9), and ICI-128,436 (2) and evaluated for their ability to inhibit partially purified bovine lens aldose reductase (in vitro) and their effectiveness to decrease galactitol accumulation in the 4-day galactosemic rat model (in vivo). In support to SAR studies, related analogues pyrimidinediones (12), dihydroquinazolones (13), and indazolidinones (14, 15) were synthesized and tested in the in vitro and in vivo assays. All prepared compounds (10-15) have shown a high level of in vitro activity (IC50 approximately 10(-6) to 4 x 10(-8) M). However, only the 2,4-quinazolinedione analogues 10 and 11, with similar N-aralkyl substitution found in 2 and 9, have exhibited good oral potency. The remaining compounds were either inactive or had only a marginal in vivo activity. The structure-activity data support the presence of a secondary hydrophobic pocket in the vicinity of the primary lipophilic region of the enzyme.

  DOI：

  10.1021/jm00108a038
• 作为产物：
  描述：

  5-溴靛红酸酐 、 3-溴丙烯 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 3.0h， 生成 1-allyl-6-bromo-1H-benzo[d][1,3]oxazine-2,4-dione
  参考文献：
  名称：

  制备4-羟基喹啉酮酯的实用方法

  摘要：

  4-羟基喹啉酮酯是许多药物的常见基序。存在几种制备这些化合物的方法，通常涉及氢化钠的使用，这引起了显着的安全性问题并且限制了它们在大规模合成中的应用。在此说明中，描述了一种实用，安全且通用的方法，该方法采用了二异丙基乙胺和叔丁醇钠的组合。这允许以良好的产率合成4-羟基喹啉酮酯和酰胺。

  DOI：

  10.1021/jo071200x

文献信息

• A Practical Method for Preparation of 4-Hydroxyquinolinone Esters
  作者：Gregory L. Beutner、Jeffrey T. Kuethe、Nobuyoshi Yasuda

  DOI：10.1021/jo071200x

  日期：2007.8.31

  4-Hydroxyquinolinone esters are a common motif for many medicinal agents. Several methods exist for preparation of these compounds, generally involving the use of sodium hydride, which raises significant safety issues and limits their application to large-scale synthesis. In this note a practical, safe, and general method that employs a combination of diisopropylethylamine and sodium tert-butoxide

  4-羟基喹啉酮酯是许多药物的常见基序。存在几种制备这些化合物的方法，通常涉及氢化钠的使用，这引起了显着的安全性问题并且限制了它们在大规模合成中的应用。在此说明中，描述了一种实用，安全且通用的方法，该方法采用了二异丙基乙胺和叔丁醇钠的组合。这允许以良好的产率合成4-羟基喹啉酮酯和酰胺。
• Quinazolineacetic acids and related analogs as aldose reductase inhibitors
  作者：Michael S. Malamas、Jane Millen

  DOI：10.1021/jm00108a038

  日期：1991.4

  A variety of 2,4-dioxoquinazolineacetic acids (10, 11) were synthesized as hybrids of the known aldose reductase inhibitors alrestatin (8), ICI-105,552 (9), and ICI-128,436 (2) and evaluated for their ability to inhibit partially purified bovine lens aldose reductase (in vitro) and their effectiveness to decrease galactitol accumulation in the 4-day galactosemic rat model (in vivo). In support to SAR studies, related analogues pyrimidinediones (12), dihydroquinazolones (13), and indazolidinones (14, 15) were synthesized and tested in the in vitro and in vivo assays. All prepared compounds (10-15) have shown a high level of in vitro activity (IC50 approximately 10(-6) to 4 x 10(-8) M). However, only the 2,4-quinazolinedione analogues 10 and 11, with similar N-aralkyl substitution found in 2 and 9, have exhibited good oral potency. The remaining compounds were either inactive or had only a marginal in vivo activity. The structure-activity data support the presence of a secondary hydrophobic pocket in the vicinity of the primary lipophilic region of the enzyme.